Our AI knew it: +72%, +60%, +59% - these picks are still climbing into Q3 results

HF Sinclair reported Q3 adjusted EPS of $11.75 versus $7.67 consensus, a 53.2% beat, while refining adjusted EBITDA rose to $2.6 billion from $661 million a year earlier; shares gained 2.88% premarket. The article also cites Microsoft revenue growth of 19% and Azure growth of 48%, and Gilead’s raised full-year product-sales guidance to $31.0–31.3 billion from $30.1–30.4 billion. Investing.com says its AI-selected portfolio has returned +118.16% since launch, but this is promotional reporting of model performance, not a broad market catalyst.

Analysis

The main signal is not proof of model alpha: selected winners and since-entry returns do not establish risk-adjusted performance, account for removed names, or show capacity and turnover costs. Treat the roster as a momentum screen, not a standalone buy list; the Nov. 1 rebalance could create small flow effects, but its impact is unknowable without assets tracking the strategies.

Near term, CVI and Amgen results are catalysts, but CVI’s refining exposure is especially vulnerable to a fast reversal in crack spreads; a strong quarter can mark peak earnings rather than a durable earnings base. For DINO, the planned turnaround adds execution and throughput risk just as the market may be extrapolating unusually favorable refining economics. The contrarian risk is that strong reported cash generation and buybacks are backward-looking while the next quarter’s margins normalize.

Microsoft’s cloud growth supports the structural case, but the second-order test is whether AI infrastructure spending converts into durable, profitable customer demand. Watch capital intensity, depreciation, and Azure growth—not headline AI enthusiasm alone. Gilead’s guidance increase is a positive company-specific signal, but does not establish a read-through to Amgen or the broader biotech group. Over 6–18 months, power availability and data-center supply constraints may shift value toward infrastructure providers, while weaker monetization would expose hyperscaler return-on-investment risk.

Key Decisions for Investors

• Do not chase DINO or CVI solely on trailing gains. For a 1–3 month refining view, wait for post-results guidance and updated crack-spread trends; reduce or hedge exposure if margins weaken or DINO’s turnaround disrupts throughput beyond management’s plan.
• Treat CVI’s Nov. 3 report as a catalyst, not a directional signal in advance. Reassess only after separating refining from fertilizer performance and checking cash generation against working-capital swings.
• Keep MSFT as a conditional structural long rather than an AI-theme proxy: add only if Azure demand remains strong while capital intensity and depreciation do not outrun operating-income growth. A sustained slowdown in Azure growth or weaker returns on AI infrastructure would falsify the thesis.
• Before acting on the model’s claimed returns, request the full live and removed-position history, benchmark and drawdown data, rebalance turnover, and strategy assets. Without these, there is no defensible estimate of net alpha or rebalance-related flow impact.